Capivasertib trials for Metastatic Breast Cancer

All Capivasertib trials · All Metastatic Breast Cancer trials

Phase breakdown

Recruiting trials studying Capivasertib for Metastatic Breast Cancer

• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
  NCT05720260 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 1 location
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 231 locations
• Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
  NCT07281833 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations

Common questions

How many trials study Capivasertib for Metastatic Breast Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.